International Patent: Treatment of subjects having lung cancer with an actionable genetic alteration using a bispecific antibody that binds EGFR and cMET

GENEVA, Sept. 18 -- MERUS B.V. filed a patent application (CN2026/081494) for “Treatment of subjects having lung cancer with an actionable genetic alteration using a bispecific antibody that binds EGFR and cMET”. With publication no. WO/2026/184653, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/46

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....